ex vivo-expanded HER2-specific T cells

BIOLOGICAL3 trials

Conditions

HER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerRecurrent Non-small Cell Lung CancerRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorStage IV Breast CancerStage IV Non-small Cell Lung Cancer

Phase 1

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

CompletedNCT00228358

University of WashingtonHER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer +6

Start: 2003-06-30Updated: 2014-11-11

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

CompletedNCT00791037

University of WashingtonHER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer +1

Start: 2008-10-31End: 2014-12-31Updated: 2017-05-25

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

WithdrawnNCT01219907

University of WashingtonHER2-positive Breast Cancer, Male Breast Cancer, Stage IV Breast Cancer

Start: 2012-06-30Updated: 2013-05-17

Journal for ImmunoTherapy of Cancer2016-04-2729 citations

Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2<sup>+</sup> breast cancer.

Journal of Clinical Oncology2014-05-203 citations

ex vivo-expanded HER2-specific T cells

Sponsors

Conditions

Phase 1

Related Papers